Rami Manochakian: Big News – Press Release by Amgen
Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, shared a post on X:
“Big News Press Release by Amgen. DeLLphi304 trial of IMDELLTRA (TARLATAMAB) vs Chemotherapy in 2nd line Tx for patients with Small Cell Lung Cancer shows: Statistically Significant and Clinically Meaningful Improvement in Overall Survival.
Read here.”
Sanjay Popat, Thoracic Oncologist at The Royal Marsden NHS Foundation Trust, shared a post by Rami Manochakian, adding:
“Yes, Big News. Anything improving survival in SCLC is massive, particularly when so many agents have been tried but failed.
Am hoping Amgen Oncology and National Institute for Health and Care Excellence can come to agreement in 2025. Will have big implications for treatment delivery
UK, are you ready?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023